Position of the Transparency Council – Tagrisso (osimertinib)
At its meeting on 16 June 2025, the Transparency Council adopted position No. 73/2025 on the appraisal of the drug Tagrisso (osimertinib) under the drug programme B.6. ‘Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)